Event Participants
Executives
3
Anish Ganatra (CFO), Nitin Kulkarni (Managing Director), Vishad Mafatlal (Executive Chairman)
Analysts
13
Abhijeet (Kotak Securities), Ankur Periwal (Axis Capital), Archit Joshi (Nuvama Wealth Management), Hiral (Shatrunjaya Investment Managers), Jason (IDBI Capital), Madhav (MLP), Pooja Swami (MUFG), Prasad (Union MF), Rohit Nagraj (360 ONE Capital), Sajal Kapoor (Antifragile Thinking), Sanjesh Jain (ICICI Securities), Siddharth Gadekar (Equirus), Vidrum Mehta (ASK Investments)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue (consolidated) | ₹1,045 crores | +44% YoY driven by growth across all three business verticals |
| HPP Business Revenue | ₹540 crores | +33% YoY on healthy volume growth and improved realizations |
| Specialty Chemicals Revenue | ₹325 crores | +48% YoY on sustained momentum, new molecule ramp-up (5 active molecules in campaign orders) |
| CDMO Revenue | ₹180 crores | +82% YoY with strong full-year outlook and deepening European partner engagement |
| EBITDA | ₹357 crores | +73% YoY |
| EBITDA Margin | 34.2% | +566 bps YoY; partially impacted by ~100 bps gross margin dip on raw material inflation, offset by productivity gains |
| Operating PBT | ₹283 crores | +101% YoY |
| PAT | ₹243 crores | +108% YoY |
| Operating Cash Flow | ₹173 crores | Robust for Q1; company became net debt-free during the quarter |
| Net Working Capital | 81 days of sales | Within financial framework |
| Net Debt Position | Net debt-free | Achieved during Q1 FY27 |
Table Rules applied: Logical order from revenue → profitability → cash flow → working capital → balance sheet.
Geographic & Segment Commentary
HPP / Refrigerants (R32 & HFO): Revenue of ₹540 crores (+33% YoY). Constructive pricing environment supported by favorable demand-supply dynamics. R32 capacity expansion of 15,000 MT on track for commissioning in Q3 FY27; the additional capacity combined with existing 9,000-10,000 MT provides significant operating leverage. Management positioning for five-year contractual offtake (35-45% of capacity target), with two contracts already signed and two more near conclusion. HFO contract with Honeywell runs through at least FY29 with an auto-extension option for a further three years.
Specialty Chemicals: Revenue of ₹325 crores (+48% YoY) with strong order visibility across existing and new molecules. Strategy focused on participating in 4-5 new campaign molecules, including three patented molecules that avoid pricing pressure typical of the agrochemical space. MPP debottlenecking on track for Q3 FY27 completion, delivering ~2x asset turn without significant new capex. Management acknowledges LATAM pricing pressure persists but differentiating through innovator-pipeline penetration rather than commodity capacity.
CDMO: Revenue of ₹180 crores (+82% YoY) with improving order visibility. Balanced portfolio across therapeutic areas (oncology, respiratory, cardiovascular, neurology, animal health). New ₹125 crore Phase 2 CGMP-4 capex (approved as part of ₹288 crore program) dedicated to the European CDMO partner, deepening participation to API minus-one level and adding a new molecule MSA in the same supply chain. Management reiterated FY28 $100M CDMO revenue target remains firmly on track; CGMP-4 capex expected to deliver 3x asset turn by FY29.
Company-Specific & Strategic Commentary
Advanced Materials — Adoption Capacity: Board approved ₹90 crore capex (funded through internal accruals) for adoption/commercial-scale qualification capacity at the Surat site, targeting data centers, electronics, semiconductors, and defense applications. Pipeline comprises ~12 niche products, including 4-5 already lab-qualified by customers. The phased approach prioritizes commercialization of the five approved products first, creating a "wheel" model where new products enter as others graduate to commercial scale. Vertical targeted to become a material business unit by end of decade, positioned as a product-plus-service play (Chemours project as service; DRDO and electronic-grade HF as product plays).
DRDO Partnership: Technology development partnership with DRDO, Ministry of Defense, to localize a critical imported specialty material for Atmanirbhar Bharat. Confidential product has applications beyond defense, which management flagged as a material addressable opportunity. Represents strategic validation of Navin's fluorination chemistry capabilities.
Chemours Liquid Cooling Project: Navin is the only supplier to Chemours for two-phase liquid cooling products, with Chemours having reported ~$1M sales in the quarter. The 15-month visibility window previously indicated by management remains valid for scale-up assessment.
Renewable Energy Initiative: ₹15.73 crore investment in a group captive hybrid renewable project (14.9 MW) to meet >60% of energy requirements from renewable sources upon operationalization, supporting both decarbonization goals and cost competitiveness for R32 production.
Capital Allocation Discipline: Sequential stage-gate approach (technical → commercial → financial) for all capex decisions; backlog of ₹3,000+ crores of planned capex over next 3-4 years on top of ~₹3,000 crores spent in last five years. Management emphasized premium-margin businesses need not be evaluated solely on asset turn, but on strategic value creation.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA Margin | 32-33% +/- 1% (near-term run-rate) | Operating leverage from HFC capacity, debottlenecking, Chemours ramp; offset by raw material cost inflation and potential lag in price pass-through |
| CDMO Revenue | $100M (FY28, on track) | Reinforced as a committed target; supported by Phase 2 CGMP-4 operationalization in Q4 FY27 and expanding European partner scope |
| CGMP-4 Asset Turn | ~3x (by FY29) | Based on ₹288 crores total CGMP capex; Phase 1 operationalized in Q3 FY26, Phase 2 on track for Q4 FY27 |
| Growth Visibility | FY28 largely baked in from existing capex | Advanced materials adoption capacity, Phase 2 CGMP, and Chemours to drive growth beyond FY28 |
| HFC R32 Commissioning | Q3 FY27 (15,000 MT) | Additional capacity equivalent to 15,000 MT R32; on track |
| MPP Debottleneck | Q3 FY27 | Progressing well |
| R32 Contractual Offtake | 35-45% of total capacity over 5 years | Two contracts signed; two more in advanced negotiation; balanced approach to retain open-position optionality |
| Renewable Energy Project | Operational (no date given) | 14.9 MW hybrid renewable, >60% energy requirement coverage |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Cost Inflation | Heightened global trade tensions are raising raw material costs; ~100 bps gross margin dip in Q1 FY27. Management expects a lag effect in passing through price increases but sees recovery through productivity initiatives. |
| HFC/Refrigerant Oversupply | India is expected to be oversupplied over the next five years as all domestic players expand; 2027 is a "free year" before quotas likely kick in from January 2028. Management mitigates via lowest-cost manufacturing position, integrated HF value chain, and renewable energy savings, but near-term R32 pricing remains outside company control. |
| CDMO FDA Readout Outcomes | One molecule readout did not come through as expected; three additional molecules expected FDA readouts in the next 8-12 months. Portfolio approach (30-40 molecules active) mitigates single-molecule failure risk. |
| Subsidiary Margin Compression (NFASL) | Consolidated minus standalone EBITDA margin dropped from 40-45% to ~32% sequentially. Management attributes to AHF transfer pricing (arm's-length transfers rather than value-added products) and campaign mix; group-level margins remain solid. |
| HFO Contract with Honeywell | Envelope extends to FY29 with auto-extension of three additional years at Honeywell's option; management does not consider this an immediate concern. |
Q&A Highlights
Advanced Materials — Capex Details and Growth Path
- Question: What are the end-use applications for the ₹90 crore adoption capex, and how should we think about growth beyond FY28? (Ankur, Axis Capital)
- Answer: Verticals focused on data centers, electronics, semiconductors, defense — including chip fabrication support, two-phase cooling, OLED displays, fire suppressants, high-purity HF, and fluoroelastomer intermediates. Products are "niche chemistries" differentiated from me-too offerings; will be a mix of product and service plays. Growth to FY28 is largely baked in from existing capex; adoption capacity, Phase 2 CGMP, and Chemours drive growth beyond that. (Anish Ganatra)
R32 Contractual Pricing and India Oversupply
- Question: Should we assume contracted R32 pricing of $5-6/kg based on the ₹600-825 crore peak revenue guidance for 15,000 MT? How does the India capacity scenario look for calendar 2027 before quotas? (Madhav, MLP)
- Answer: The asset-turn figures in the deck are unchanged from capex approval; the real competitive advantage is Navin's lowest-cost manufacturing position (integrated HF chain, renewable energy savings). India will be oversupplied for five years — analysis must be global, not India-specific. Customers increasingly seek 5-year contractual commitments; target is 35-45% of capacity contracted, balanced with open positions. Navin's operating leverage on R32, even in a weak pricing environment, will protect group EBITDA. (Anish Ganatra)
CDMO — Dedicated Capacity and Supply Chain Position
- Question: Is the new capacity entirely for the existing European contract, and does "API minus one" mean matching competition in supply chain? (Rohit Nagraj, 360 ONE)
- Answer: Yes, the new capacity (Phase 2 CGMP-4) is dedicated to the European partner, reflecting increasing demand on the molecule and an additional MSA for a second molecule in the same supply chain, effectively reaching API-minus-one participation. Management did not confirm whether competitors hold similar roles. On ₹288 crores capex, asset turn of 3x is expected (by FY29); revenue potential is ~₹900 crores from this program. (Anish Ganatra)
CDMO Pipeline and FDA Readouts
- Question: After one readout disappoint, how are lateral entries looking for FY27-28? (Sanjesh Jain, ICICI Securities)
- Answer: Portfolio approach is key — three more molecules are expected to go through FDA readouts in the next 8-12 months, across different global majors. Pipeline of 30-40 active molecules, ~10 late-stage; "enough in the pipeline to not worry about an outlier." (Anish Ganatra)
Subsidiary Margin Compression (Consolidated minus Standalone)
- Question: Subsidiary EBITDA margin dropped from 40-45% to ~32% sequentially (12pp). Is there a call-out? (Sanjesh Jain, ICICI Securities)
- Answer: Two factors: campaign-based revenue mix varies quarter to quarter with different margin profiles; and AHF capacity commissioning at Dahej means arm's-length AHF transfers to Surat (raw material) instead of value-added product transfers. Group-level margins remain solid; downstream value-add capacity in the subsidiary will restore margin accretion over time. (Anish Ganatra)
Specialty Chemicals — Volume-led Growth Trajectory
- Question: After subdued FY25, is current growth predominantly volume-led with minimal pricing contribution, and what is the FY27 trajectory? (Jason, IDBI Capital)
- Answer: Growth is driven by participation in five new campaign molecules (three patented, less pricing pressure), which signals deepening and broadening of customer relationships. Management does not expect return of 30%+ EBITDA margins in Specchem; philosophy is productivity-driven and efficiency-driven. MPP debottlenecking delivers ~2x asset turn, "unheard of" in agrochemical space historically, reflecting differentiated navigation. (Anish Ganatra)
AHF Capacity / Utilization Disclosure
- Question: How much of the 60,000 MT AHF capacity is captive vs. external sales? (Jason, IDBI Capital)
- Answer: Management declined to disclose specific numbers; indicated interim downstream AHF sales will continue until own downstream capacities (advanced materials, etc.) absorb it. The 60,000 MT is sufficient for the next 4-5 years of planned growth; further expansion possible if required. (Anish Ganatra)
CDMO — Breadth vs. Depth of European Relationship
- Question: What evidence should investors look for that CDMO is broadening across customers, not just deepening one relationship? (Sajal Kapoor, Antifragile Thinking)
- Answer: Deepening the European relationship builds a strong base load. Watch for: FDA readouts converting to commercial volumes (3-4 molecules in next 8-12 months), new capacity announcements, and announcements of additional customers. Portfolio continuously refreshed across 30-40 molecules. "Walk-the-talk" execution track record is the demonstration. (Anish Ganatra)
R32 / HFC Contract Details and AHF Outlook
- Question: Is there a live or emerging contract for R32, and what's the AHF capacity utilization? (Archit Joshi, Nuvama)
- Answer: Two R32 contracts already signed; two more in advanced stage of conclusion. Beyond target of 35-45% of capacity contracted, management will refuse additional contracts to retain open-position flexibility. AHF utilization not disclosed; 60,000 MT sufficient for next 4-5 years. (Anish Ganatra)
Margin Outlook — Structural vs. Cyclical
- Question: Q4 FY26 to Q1 FY27 margins flat despite favorable mix shift (HPP+CDMO up from 62% to 69%). How should we interpret structural margin trajectory? (Vidrum Mehta, ASK Investments)
- Answer: Q1 FY26 benefited from high HF prices; today's environment has raw material cost inflation (global supply chain risk). Gross margins dipped ~100 bps QoQ but were offset by fixed-cost productivity. Guidance: 32-33% EBITDA margin +/- 1% is a fair normalized run-rate assumption, with operating leverage from new HFC capacity, debottlenecking, and Chemours ramp. (Anish Ganatra)
Capex Scale — Revenue Visibility and Asset Turns
- Question: With ~₹6,000 crores of cumulative capex over 7-8 years, what revenue visibility or order backlog underpins this? (Vidrum Mehta, ASK Investments)
- Answer: Capex pursued only when value-accretive (stage-gated: technical → commercial → financial clearance). Asset-turn metrics are less relevant for high-margin businesses; product plays (like adoption capacity) are backed by lab-scale customer qualifications, while service contracts (like Chemours) are backed by order projections. "Shades of gray" in product-side visibility; stage gates de-risk capital allocation. (Anish Ganatra)
Advanced Materials — Pilot vs. Dedicated Capacity
- Question: Is the ₹90 crore capex a pilot plant or dedicated commercial capacity? (Siddharth Gadekar, Equirus)
- Answer: It's "adoption capacity" — distinct from pilot scale because products are already lab-qualified by customers. Creates two core platforms and augments analytical/equipment capabilities at Surat. Scale-up risk exists but managed through portfolio breadth. (Anish Ganatra)
HFO/Honeywell Contract
- Question: How should we think about the HFO revenue (₹460-470 crores annually) beyond FY27, given it was a 5-year contract? (Siddharth Gadekar, Equirus)
- Answer: Original term is seven years (commercialized July 2022) with auto-extension of three years at Honeywell's option. Ample runway — not a near-term concern. (Anish Ganatra)
DRDO Order — Revenue and Margin Impact
- Question: What will the DRDO order mean for revenues and margins? (Hiral, Shatrunjaya Investment Managers)
- Answer: Confidentiality-bound; product name is public. Product has applications beyond defense, which is also a material opportunity. No quantitative guidance provided. (Anish Ganatra)
Key Takeaway
Navin Fluorine delivered a stellar Q1 FY27 with consolidated revenue of ₹1,045 crores (+44% YoY), EBITDA of ₹357 crores (+73%), and PAT of ₹243 crores (+108%), with all three verticals — HPP (₹540 crores, +33%), Specialty Chemicals (₹325 crores, +48%), and CDMO (₹180 crores, +82%) — contributing meaningfully. The company became net debt-free during the quarter, freeing up balance-sheet capacity for its next investment cycle. Strategically, the quarter was defined by three structural announcements: a ₹90 crore adoption-capacity capex for advanced materials (targeting data centers, semiconductors, defense with 4-5 customer lab-qualified products), a ₹125 crore Phase 2 CGMP-4 capex deepening the European CDMO relationship to API-minus-one level, and a DRDO partnership for an indigenous specialty material. Management guided to a sustained EBITDA margin of 32-33% (±1%) while reiterating the $100M CDMO revenue target for FY28 and 3x asset-turn on the ₹288 crore CGMP program by FY29. R32 capacity (15,000 MT) and MPP debottlenecking are both on track for Q3 FY27 commissioning, and two five-year R32 supply contracts are already signed against a 35-45% target. Key watch-points include raw-material inflation pass-through lag, India HFC oversupply through the decade (mitigated by lowest-cost position and contractual offtake), and translation of the CDMO FDA-readout pipeline (three molecules in the next 8-12 months) into commercial-scale contracts. The advanced-materials wheel — with ~12 niche products progressing from lab to commercial qualification — is positioned to become a material business vertical by the end of the decade.